Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.

NCT00840333 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00840333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00840333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
December 31, 2009
Enrollment
27 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis